DK2958888T3 - Bicykliske forbindelser - Google Patents

Bicykliske forbindelser Download PDF

Info

Publication number
DK2958888T3
DK2958888T3 DK14709822.2T DK14709822T DK2958888T3 DK 2958888 T3 DK2958888 T3 DK 2958888T3 DK 14709822 T DK14709822 T DK 14709822T DK 2958888 T3 DK2958888 T3 DK 2958888T3
Authority
DK
Denmark
Prior art keywords
compound
mmol
salt
compounds
formula
Prior art date
Application number
DK14709822.2T
Other languages
English (en)
Inventor
T G Murali Dhar
Hai-Yun Xiao
Alaric J Dyckman
Eric J Chan
Marta Dabros
Daniel Richard Roberts
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK2958888T3 publication Critical patent/DK2958888T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
    • C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Claims (13)

  1. BICYKLISKE FORBINDELSER
    1. Forbindelse med formlen (I):
    ogbllcr et salt deraf; hvor R er -OH eller -0P(0)(0H)2.
  2. 2. Forbindelse ifølge krav 1 eller et salt deraf, hvor R er -OH.
  3. 3. Forbindelse ifølge krav 1 eller et salt deraf, hvor R er -0P(0)(0H)2.
  4. 4. Forbindelse ifølge krav 1 eller et salt deraf, hvilken forbindelse har strukturen;
  5. 5. Forbindelse ifølge krav 1 eller et salt deraf, hvilken forbindelse har strukturen;
  6. 6. Forbindelse ifølge krav 5 eller et salt deraf, hvor forbindelsen eller saltet er et krystallinsk faststof.
  7. 7. Forbindelse ifølge krav 1 eller et salt deraf, hvilken forbindelse har strukturen;
  8. 8. Forbindelse ifølge krav 1 eller et salt deraf, hvilken forbindelse har strukturen;
  9. 9. Farmaceutisk sammensætning, der omfatter en forbindelse ifølge et hvilket som helst af kravene 1 til 8 eller farmaceutisk acceptabelt salt deraf; og farmaceutisk acceptabel bærer.
  10. 10. Forbindelse ifølge et hvilket som helst af kravene 1 til 8 eller salt deraf til anvendelse i terapi.
  11. 11. Forbindelse ifølge et hvilket som helst af kravene 1 til 8 eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling af en sygdom eller forstyrrelse, der er forbundet med aktiviteten af G proteinkoblet receptor SIPi.
  12. 12. Forbindelse ifølge et hvilket som helst af kravene 1 til 8 eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling af en autoimmun sygdom eller en kronisk inflammatorisk sygdom.
  13. 13. Forbindelse ifølge krav 12, hvor den autoimmune sygdom eller kroniske inflammatoriske sygdom er udvalgt fra lupus, multipel sklerose, inflammatorisk tarmsygdom og rheumatoid artritis.
DK14709822.2T 2013-02-21 2014-02-21 Bicykliske forbindelser DK2958888T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767531P 2013-02-21 2013-02-21
PCT/US2014/017534 WO2014130752A2 (en) 2013-02-21 2014-02-21 Bicyclic compounds

Publications (1)

Publication Number Publication Date
DK2958888T3 true DK2958888T3 (da) 2017-03-06

Family

ID=50272738

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14709822.2T DK2958888T3 (da) 2013-02-21 2014-02-21 Bicykliske forbindelser

Country Status (35)

Country Link
US (3) US9115054B2 (da)
EP (1) EP2958888B1 (da)
JP (1) JP6277210B2 (da)
KR (1) KR102242265B1 (da)
CN (1) CN105026362B (da)
AR (1) AR094851A1 (da)
AU (1) AU2014218883B2 (da)
BR (1) BR112015019919A2 (da)
CA (1) CA2902168C (da)
CL (1) CL2015002358A1 (da)
CY (1) CY1118641T1 (da)
DK (1) DK2958888T3 (da)
EA (1) EA025294B1 (da)
ES (1) ES2613262T3 (da)
HK (1) HK1218111A1 (da)
HR (1) HRP20170247T1 (da)
HU (1) HUE031626T2 (da)
IL (1) IL240613B (da)
LT (1) LT2958888T (da)
MA (1) MA38425B1 (da)
MX (1) MX2015010347A (da)
MY (1) MY173990A (da)
PE (1) PE20151746A1 (da)
PH (1) PH12015501793A1 (da)
PL (1) PL2958888T3 (da)
PT (1) PT2958888T (da)
RS (1) RS55703B1 (da)
SG (1) SG11201506408TA (da)
SI (1) SI2958888T1 (da)
SM (1) SMT201700115B (da)
TN (1) TN2015000356A1 (da)
TW (1) TWI613182B (da)
UY (1) UY35338A (da)
WO (1) WO2014130752A2 (da)
ZA (1) ZA201506965B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10077236B2 (en) 2013-07-15 2018-09-18 The Regents Of The University Of California Azacyclic constrained analogs of FTY720
TWI689487B (zh) * 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
WO2017053990A1 (en) * 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
EP3507278B1 (en) 2016-09-02 2021-01-27 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
WO2021062168A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
EP1482895A4 (en) 2002-03-01 2005-04-27 Merck & Co Inc AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
AR044402A1 (es) 2003-05-19 2005-09-14 Irm Llc Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc 3,4-DISUSBSTITUTED PROPANOIC CARBOXYLATES AS S1P RECEPTOR AGONISTS (EDG)
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
JP2008530135A (ja) 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに５員の複素環を含むスフィンゴシン＝１−リン酸アゴニスト
AU2006245438A1 (en) 2005-02-18 2006-11-16 Bellus Health (Innodia) Inc. Analogs of 4-hydroxyisoleucine and uses thereof
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
JP5072825B2 (ja) 2005-03-23 2012-11-14 アクテリオン ファーマシューティカルズ リミテッド スフィンゴシン−１−ホスフェート−１受容体アゴニストとしての新規チオフェン誘導体
CA2605594A1 (en) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
CA2619101A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
RU2430913C2 (ru) 2006-01-06 2011-10-10 Сепракор Инк. Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
MX2008009579A (es) 2006-01-27 2008-09-25 Univ Virginia Metodo para el tratamiento de dolor neuropatico.
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
EP2010524A2 (en) 2006-03-21 2009-01-07 Epix Delaware, Inc. S1p receptor modulating compounds
EP2001472A2 (en) 2006-03-23 2008-12-17 Merck and Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
BRPI0709866B8 (pt) 2006-04-03 2021-05-25 Astellas Pharma Inc compostos héteros e composição farmacêutica compreendendo ditos compostos
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
KR101454937B1 (ko) 2006-09-08 2014-10-27 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-3-일 유도체
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
BRPI0720478A2 (pt) * 2006-12-21 2014-01-14 Abbott Laboratoires Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato
CN101610674A (zh) * 2006-12-21 2009-12-23 艾博特公司 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
KR101174191B1 (ko) 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
JP5517944B2 (ja) 2007-11-01 2014-06-11 アクテリオン ファーマシューティカルズ リミテッド 新規なピリミジン誘導体
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US8153686B2 (en) 2008-04-01 2012-04-10 Theravance, Inc. Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
CN102245602B (zh) 2008-12-18 2014-09-10 默克雪兰诺有限公司 用于治疗多发性硬化症的与恶二唑稠合的杂环衍生物
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2382212B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP2012515788A (ja) * 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
WO2010093616A1 (en) 2009-02-10 2010-08-19 Abbott Laboratories Methods for preparing s1p receptor agonists and antagonists
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
AU2010319879A1 (en) 2009-10-29 2012-06-14 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
EP2560969B1 (en) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260178A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
CN103124727B (zh) 2010-07-20 2015-03-25 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
US9682078B2 (en) 2011-03-18 2017-06-20 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
WO2012147311A1 (ja) 2011-04-26 2012-11-01 パナソニック株式会社 暖房システム及び暖房システム制御方法
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
WO2014018891A1 (en) 2012-07-27 2014-01-30 Biogen Idec Ma Inc. Compounds that are s1p modulating agents and/or atx modulating agents

Also Published As

Publication number Publication date
SI2958888T1 (sl) 2017-01-31
PH12015501793B1 (en) 2015-11-09
JP6277210B2 (ja) 2018-02-07
PE20151746A1 (es) 2015-12-02
IL240613A0 (en) 2015-10-29
MX2015010347A (es) 2015-11-16
WO2014130752A3 (en) 2014-10-23
JP2016513124A (ja) 2016-05-12
US20150315128A1 (en) 2015-11-05
AU2014218883B2 (en) 2017-05-11
WO2014130752A2 (en) 2014-08-28
CN105026362B (zh) 2017-07-14
CA2902168C (en) 2019-01-08
TN2015000356A1 (en) 2017-01-03
ZA201506965B (en) 2017-08-30
LT2958888T (lt) 2017-02-10
EP2958888B1 (en) 2016-11-23
ES2613262T3 (es) 2017-05-23
PT2958888T (pt) 2017-02-03
US9115054B2 (en) 2015-08-25
AR094851A1 (es) 2015-09-02
CA2902168A1 (en) 2014-08-28
PL2958888T3 (pl) 2017-07-31
MY173990A (en) 2020-03-03
UY35338A (es) 2014-08-29
SMT201700115B (it) 2017-03-08
MA38425B1 (fr) 2019-03-29
RS55703B1 (sr) 2017-07-31
CN105026362A (zh) 2015-11-04
KR102242265B1 (ko) 2021-04-19
PH12015501793A1 (en) 2015-11-09
US9487481B2 (en) 2016-11-08
HRP20170247T1 (hr) 2017-04-07
EA201591409A1 (ru) 2015-12-30
HK1218111A1 (zh) 2017-02-03
CL2015002358A1 (es) 2016-02-26
EA025294B1 (ru) 2016-12-30
US9359286B2 (en) 2016-06-07
CY1118641T1 (el) 2017-07-12
KR20150119352A (ko) 2015-10-23
TWI613182B (zh) 2018-02-01
HUE031626T2 (en) 2017-07-28
EP2958888A2 (en) 2015-12-30
AU2014218883A1 (en) 2015-10-15
MA38425A1 (fr) 2017-12-29
IL240613B (en) 2018-06-28
US20160251309A1 (en) 2016-09-01
BR112015019919A2 (pt) 2017-07-18
US20140235591A1 (en) 2014-08-21
TW201444786A (zh) 2014-12-01
SG11201506408TA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
DK2958888T3 (da) Bicykliske forbindelser
US11701373B2 (en) Substituted bicyclic compounds
US11046646B2 (en) Alkylphenyl compounds
WO2019032631A1 (en) OXIME ETHER COMPOUNDS
WO2018045149A1 (en) Substituted tricyclic heterocyclic compounds